sirtinol

Sirtinol is a synthetic small molecule and member of the benzamide chemical class, primarily characterized as a selective inhibitor of the NAD+-dependent deacetylase enzymes SIRT1 and SIRT2 (sirtuin 1 and 2)[1][3][4][5]. By inhibiting these class III histone deacetylases, sirtinol can alter protein acetylation, affecting key cellular processes such as cell cycle regulation, apoptosis, senescence, metabolism, and stress responses[3][6]. Sirtinol has demonstrated anticancer activity through the induction of both apoptotic and autophagic cell death, G1 cell cycle arrest, and modulation of the tumor suppressor p53 acetylation[3]. Furthermore, its SIRT2-inhibitory activity modulates gluconeogenesis by destabilizing the metabolic enzyme PEPCK1, suggesting potential applications in metabolic disorders including diabetes[4]. Sirtinol has also been shown to reduce metastasis and modulate immune cell environments in preclinical cancer models, such as breast cancer[2]. Developed originally by The Howard Hughes Medical Institute, sirtinol remains in preclinical investigative stages for oncology and metabolic diseases[1].

Other names

2-{[(2-hydroxy-1-naphthyl)methylene]amino}-N-(1-phenylethyl)benzamide410536-97-9CHEBI:73158